Janux Therapeutics, Inc.
JANX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$68,994 | -$58,293 | -$63,059 | -$32,672 |
| Dep. & Amort. | $2,060 | $1,955 | $841 | $113 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $33,020 | $20,005 | $17,203 | $6,910 |
| Change in WC | $685 | -$6,554 | $4,276 | $8,842 |
| Other Non-Cash | -$10,585 | -$7,688 | -$2,183 | -$169 |
| Operating Cash Flow | -$43,814 | -$50,575 | -$42,922 | -$16,976 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$359 | -$1,850 | -$6,445 | -$1,482 |
| Net Acquisitions | $0 | $0 | -$64,711 | $339,481 |
| Inv. Purchases | -$470,577 | -$317,344 | -$294,389 | -$473,626 |
| Inv. Sales/Matur. | $212,915 | $278,000 | $359,100 | $134,145 |
| Other Inv. Act. | $0 | $0 | $64,711 | -$339,481 |
| Investing Cash Flow | -$258,021 | -$41,194 | $58,266 | -$340,963 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $698,267 | $56,530 | $500 | $204,167 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $14,968 | $3,018 | $0 | $182,357 |
| Financing Cash Flow | $713,235 | $59,548 | $500 | $386,524 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $411,400 | -$32,221 | $15,844 | $28,585 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $20,021 | $52,242 | $36,398 | $7,813 |
| End Cash | $431,421 | $20,021 | $52,242 | $36,398 |
| Free Cash Flow | -$44,173 | -$52,425 | -$49,367 | -$18,458 |